Last reviewed · How we verify

Aromatase Inhibitor and Growth Hormone

Nemours Children's Clinic · Phase 3 active Small molecule

Aromatase Inhibitor and Growth Hormone is a Aromatase inhibitor + Growth hormone combination Small molecule drug developed by Nemours Children's Clinic. It is currently in Phase 3 development for Growth hormone deficiency in children, Short stature in pediatric patients. Also known as: Arimidex (Anastrozole), Femara (Letrozole), Nutropin (Somatropin), Genotropin (Somatropin).

This combination therapy inhibits aromatase to reduce estrogen production while supplementing growth hormone to promote linear growth in pediatric patients.

This combination therapy inhibits aromatase to reduce estrogen production while supplementing growth hormone to promote linear growth in pediatric patients. Used for Growth hormone deficiency in children, Short stature in pediatric patients.

At a glance

Generic nameAromatase Inhibitor and Growth Hormone
Also known asArimidex (Anastrozole), Femara (Letrozole), Nutropin (Somatropin), Genotropin (Somatropin)
SponsorNemours Children's Clinic
Drug classAromatase inhibitor + Growth hormone combination
TargetAromatase (CYP19A1) and growth hormone receptor (GHR)
ModalitySmall molecule
Therapeutic areaPediatric Endocrinology
PhasePhase 3

Mechanism of action

Aromatase inhibitors block the conversion of androgens to estrogen, which can help delay epiphyseal closure and extend the growth window in children with growth disorders. Concurrent growth hormone supplementation directly stimulates linear growth through IGF-1 signaling and anabolic effects on bone and muscle tissue. Together, these agents aim to maximize final adult height in growth-hormone-deficient or growth-restricted pediatric populations.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Aromatase Inhibitor and Growth Hormone

What is Aromatase Inhibitor and Growth Hormone?

Aromatase Inhibitor and Growth Hormone is a Aromatase inhibitor + Growth hormone combination drug developed by Nemours Children's Clinic, indicated for Growth hormone deficiency in children, Short stature in pediatric patients.

How does Aromatase Inhibitor and Growth Hormone work?

This combination therapy inhibits aromatase to reduce estrogen production while supplementing growth hormone to promote linear growth in pediatric patients.

What is Aromatase Inhibitor and Growth Hormone used for?

Aromatase Inhibitor and Growth Hormone is indicated for Growth hormone deficiency in children, Short stature in pediatric patients.

Who makes Aromatase Inhibitor and Growth Hormone?

Aromatase Inhibitor and Growth Hormone is developed by Nemours Children's Clinic (see full Nemours Children's Clinic pipeline at /company/nemours-children-s-clinic).

Is Aromatase Inhibitor and Growth Hormone also known as anything else?

Aromatase Inhibitor and Growth Hormone is also known as Arimidex (Anastrozole), Femara (Letrozole), Nutropin (Somatropin), Genotropin (Somatropin).

What drug class is Aromatase Inhibitor and Growth Hormone in?

Aromatase Inhibitor and Growth Hormone belongs to the Aromatase inhibitor + Growth hormone combination class. See all Aromatase inhibitor + Growth hormone combination drugs at /class/aromatase-inhibitor-growth-hormone-combination.

What development phase is Aromatase Inhibitor and Growth Hormone in?

Aromatase Inhibitor and Growth Hormone is in Phase 3.

What are the side effects of Aromatase Inhibitor and Growth Hormone?

Common side effects of Aromatase Inhibitor and Growth Hormone include Gynecomastia (reduced by aromatase inhibition), Injection site reactions (growth hormone), Headache, Arthralgia, Fluid retention.

What does Aromatase Inhibitor and Growth Hormone target?

Aromatase Inhibitor and Growth Hormone targets Aromatase (CYP19A1) and growth hormone receptor (GHR) and is a Aromatase inhibitor + Growth hormone combination.

Related